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Abstract
Background: Diabetes mellitus is a metabolic disorder of multiple aetiology characterised by hyperglycemia resulting
from defects in insulin secretion, insulin action or both. It is a global epidemic ravaging both developed and developing
countries. The situation will worsen if nothing is done urgently. In fact, the need to identify natural products with
antidiabetic potentials is of great importance as supported by several research efforts all over the world, in search of
antidiabetic plant based products that are safe and efficacious. Available literatures show that several phytochemicals with
antidiabetic properties have been identified in certain plants amongst which include Uvaria chamae. The potentials of
Uvaria chamae as an antidiabetic and hypolipidemic drug-candidate are thus tested.
Methods: Diabetes mellitus was experimentally induced after the rats were fasted overnight by administering
intraperitoneally, 60 mg/kg streptozotocin. After 72 h, the rats with plasma glucose levels >200 mg/dl were classified as
diabetic. A total of six groups containing five rats per group were used. One group of diabetic rats was untreated. Three
diabetic groups, each were treated orally with 100, 250 and 400 mg/kg body weight of the extract. Another diabetic
group was treated with insulin (0.5 IU/kg) subcutaneously. The control received 0.5 ml (2% solution) of acacia orally. The
treatment was for 8 days. The effects of the extract on weight, plasma glucose and other biochemical parameters were
evaluated using standard procedures.
Results: The diabetic rats treated with the extract showed significant reductions (p < 0.05) in weight, plasma glucose
levels, low density lipoprotein and cholesterol compared with the control. The 100, 250 and 400 mg/kg body weight of
the extract showed maximum glucose reduction of 85.16, 81.50 and 86.02% respectively. Histologically the pancreas of
the diabetic rats treated with the extract, showed clusters of variably sized regenerated islet of Langerhans within sheets
of normal exocrine pancreas, while the pancreas of diabetic rats treated with insulin showed no islet of Langerhans.
Conclusion: The study showed that Uvaria chamae caused weight loss and has good hypoglycemic and hypolipidemic
activities that may reduce the risk of developing cardiovascular diseases.
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Background
Diabetes mellitus has been described as a metabolic dis-
order of multiple aetiology, and characterized by chronic
hyperglycemia with disturbances of carbohydrate, fat, and
protein metabolism, resulting from defects in insulin secre-
tion, insulin action or both [1, 2]. It is one of the oldest
diseases of mankind that affects millions of people world-
wide [3]. The number of people living with the disease is
expected to double with major impact on the population of
the developing countries due to increased rate of
industrialization [3, 4]. It is a major risk factor for the devel-
opment of cardiovascular disease [5]. Hence, the need to re-
duce the risk of vascular complications by securing
adequate glycemic, lipidemic, blood pressure and weight
control [6]. Currently diabetes is controlled by diet, exer-
cise, oral hypoglycemic agents and insulin therapy [7]. The
high level of treatment failures, unpleasant side effects and
enormous cost associated with diabetic therapy have gener-
ated an urgent need and desire for alternative treatments
[8]. However, the preferred choice of plant medicine by
many might not be unconnected with the historical suc-
cesses recorded in the use of herbal products in traditional
system of medicine in the management of diabetes mellitus
[9]. One of such plants used traditionally in the manage-
ment of diabetes mellitus is Uvaria chamae.
Uvaria chamae is a medicinal plant that belongs to the
family, Annonaceae. It is a climbing plant commonly found
in West Africa [9]. In this region of the world, it is identi-
fied by numerous names such as: Ogholo by the Esan
people of Edo state, Ayiloko by the Igalas, Kaskaifi by the
Hausas, Oko oja by the Yorubas, Mmimi ohia by the Igbos
in Nigeria and Akotompo by the Akan-fante people of
Ghana [9]. The health benefits of medicinal plants are at-
tributed in part to their unique phytochemical composition
[10]. The phytochemical analysis of the leaves and roots of
Uvaria chamae revealed the presence of alkaloids, glyco-
sides, saponin, tannins, flavonoids, terpenoids and phenols
[11, 12]. Our previous study on the preliminary phyto-
chemical screening and evaluation of hypoglycemic proper-
ties of Uvaria chamae also revealed that the extract has
secondary metabolites such as alkaloids, flavonoids, tannins
and terpenoids which corroborate earlier works done on
the phytochemical screening of this plant. The study
showed that the hypoglycemic properties of Uvaria chamae
may be accounted for by the presence of the phyto-
chemicals [9]. The anti-fungal, anti-malarial and anti-
inflammatory activities of Uvaria chamae have also been
reported [11, 13, 14]. However, no scientific study has been
conducted on the antidiabetic activity of this plant. The
present study therefore was designed to evaluate the antidi-
abetic and hypolipidemic activities of the hydroethanolic




The roots of Uvaria chamae were obtained from a farm
in Uromi, Edo State, Nigeria during the rainy season. They
were authenticated by a taxonomist, Mr T. K. Odewo, of
Department of Botany, University of Lagos, Nigeria. The
voucher specimen with number LUH 3572 was deposited
in the University herbarium.
Preparation of the plant material for extraction
The roots were washed with clean water to remove foreign
materials, chopped into small pieces and dried in an oven
at 45° centigrade for 4 days. They were ground to coarse
powder with electric grinder. The root powder, 500 g, was
extracted with 93.3% hydroethanol by maceration with fre-
quent stirring for 5 days. The extract was filtered using
Whatman filter paper number 4 and concentrated with a
rotary evaporator at a reduced pressure. The concentrated
extract was dried in an oven at 40° centigrade to obtain
22.41 g dry residue (4.48% yields).
Animals
Albino rats (160 ± 20 g) of both sexes were obtained from
the Laboratory Animal Center, College of Medicine,
University of Lagos, Idi-Araba and kept under standard en-
vironmental condition of 12/12 h light/dark cycle. They
were housed in cages (5 animals per cage), maintained on
standard animal pellets (Pfizer Feeds Plc, Nigeria), and
Table 1 Effect of Uvaria chamae on Fasting Blood Glucose (FBG) Levels (mg/dl) and % Reduction (% R) of FBG levels
Group Day0 Day1 Day5 %R in Day5 Day 8 %R in Day8
I 74.33 ± 0.88 75.66 ± 2.19 86.00 ± 3.22 ……. 90.67 ± 6.17 …….
II 59.33 ± 2.91 363.00 ± 50.5* 270.70 ± 33.17* 25.43 133.30 ± 10.04* 63.28
III 63.33 ± 0.67 303.00 ± 7.10* 44.00 ± 7.00* 85.48 42.37 ± 0.52* 86.02
IV 54.67 ± 1.45 263.30 ± 3.84* 52.67 ± 7.27* 80.00 48.70 ± 1.04* 81.50
V 66.67 ± 3.93 325.70 ± 17.85* 46.00 ± 2.08* 85.16 48.33 ± 0.88* 85.16
VI 60.00 ± 4.36 242.30 ± 3.93* 256.30 ± 1.86* −5.66 300.30 ± 2.03* −23.94
*Significant difference (p < 0.05; n = 5) between the Mean ± SEM of test group vs. control. Group I = (control) Normal rats received 0.5 ml (2% solution) of acacia,
II = diabetic rats treated with insulin 0.5I.U/kg, III = diabetic rats treated with 400 mg/kg extract, IV = diabetic rats treated with 250 mg/kg extract, V = diabetic rats
treated with 100 mg/kg extract, VI = diabetic rats untreated
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provided with water ad libitum. They were allowed to
acclimatize for 7 days to the laboratory conditions before
the experiment. The use and care of the animals, and the
experimental protocol were in strict compliance with the
National Research Council guidelines on the care and use
of laboratory animals [15]. The experimental protocol (with
Protocol ID: RGEEC/21/2015) was approved by the
research grants and experimentation Ethics committee of
the College of Medicine, University of Lagos, Nigeria.
Diabetic study
The dose selection for the diabetic study was guided by
the result obtained from the oral acute toxicity study
done in our previous work which showed that the me-
dian lethal dose was 7.08 g/kg body weight [9].
Diabetes mellitus was experimentally induced in the
rats after an overnight fast by administering intraperito-
neally (IP) 60 mg/kg streptozotocin dissolved in 0.1 M
citrate buffer of PH 4.5 [16]. After 72 h, the blood glu-
cose levels were monitored with a glucometer (Accu-
Chek, Roche Diagnostics) and the rats with plasma glu-
cose levels > 200 mg/dl were classified as diabetic [17]
and were included in the study. A total of six groups
containing five rats per group were used. Five groups
were diabetic while the remaining group was used as a
control. The rats were treated daily for 8 days orally ex-
cept for those that were given insulin subcutaneously.
The treatment was as follows:
Group I: control given 0.5 ml (2% solution) of acacia
Group II: Induced diabetic rats treated daily
subcutaneously with (soluble) insulin 0.5 I.U / kg body
weight
Group III: Induced diabetic rats treated daily with
400 mg/kg of the extract
Group IV: Induced diabetic rats treated daily with
250 mg/kg of the extract
Group V: Induced diabetic rats treated daily with
100 mg/kg of the extract
Group VI: Induced diabetic rats untreated
The rats were weighed and blood samples were col-
lected from the tail vein for fasting blood glucose levels
from the beginning of the treatment, the 5th day and at
the end of the treatment (the 8th day). On the 8th day,
blood was obtained via ocular puncture into heparinised
containers for biochemical profile.
Sample analysis
The heparinised blood was centrifuged within 5 min of col-
lection at 4000 g for 10 min to obtain plasma, that was ana-
lysed for total cholesterol (Chol), triglyceride (TG), and
High density lipoprotein-cholesterol (HDL-cholesterol)
levels by modified enzymatic procedures from Sigma Diag-
nostics [18]. Low density lipoprotein-cholesterol (LDL-chol-
esterol) levels were calculated using the Friedwald equation
[19]. Plasma was analysed for alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phos-
phatase (ALP) and creatinine by standard enzymatic assay
analysis [20]. The plasma protein contents and plasma
Table 3 Effect of Uvaria chamae on other biochemical parameters on the 8th Day
Parameter Group I Group II GroupIII GroupIV GroupV Group VI
Protein (g/L) 34.9 ± 0.1 25.7 ± 0.9 20.0 ± 2.3* 35.0 ± 1.2 23.7 ± 0.3 15.0 ± 2.0*
ALB (mg/dl) 43.9 ± 0.3 25.3 ± 1.5* 16.3 ± 1.5* 37.3 ± 0.9 27.0 ± 0.6 33.3 ± 1.2
Creatinine (mg/dl) 0.6 ± 0.01 1.0 ± 0.03 1.0 ± 0.1 1.03 ± 0.2 0.8 ± 0.1 1.13 ± 0.1*
Urea mg/dl 27.7 ± 0.9 56.0 ± 0.6* 64.0 ± 0.6* 43.3 ± 0.9* 31.0 ± 0.6 46.3 ± 2.3*
AST (U/L) 12.6 ± 0.2 27.2 ± 0.2* 13.3 ± 2.2 16.3 ± 0.3 13.8 ± 0.2 31.1 ± 1.8*
ALT (U/L) 10.8 ± 0.5 22.3 ± 1.3* 11.3 ± 2.2 14.8 ± 0.4 12.8 ± 0.4 27.7 ± 0.7*
ALP (U/L) 13.0 ± 0.3 30.7 ± 0.7* 14.7 ± 2.3 23.7 ± 5.7 16.7 ± 1.2 17.8 ± 0.03
*Significant difference (p < 0.05; n = 5) between the Mean ± SEM of test group vs. control. Group I = (control) Normal rats received 0.5 ml (2% solution) of acacia,
II = diabetic rats treated with insulin 0.5I.U/kg, III = diabetic rats treated with 400 mg/kg extract, IV = diabetic rats treated with 250 mg/kg extract, V = diabetic rats
treated with 100 mg/kg extract, VI = diabetic rats untreated
Table 2 Effect of Uvaria chamae on Plasma Lipid Profile (mg/dl)
Parameter Group I GroupII GroupIII GroupIV GroupV Group VI
Chol 126.3 ± 2.3 78.0 ± 0.6* 72.3 ± 0.9* 70.0 ± 14.4* 89.33 ± 0.9* 107.0 ± 0.6
TG 43.2 ± 0.6 42.3 ± 1.9 57.3 ± 8.2 34.7 ± 0.3 61.3 ± 1.9 73.7 ± 0.9*
HDL 24.4 ± 0.4 25.3 ± 1.9 36.3 ± 4.1 31.7 ± 0.9 30.7 ± 0.7 29.7 ± 1.5
LDL 93.3 ± 0.6 44.2 ± 1.9 * 24.5 ± 7.8* 31.36 ± 7.13* 46.37 ± 1.53* 62.56 ± 2.52
*significant difference (p < 0.05; n = 5) between the Mean ± SEM of test group vs. control. Group I = (control) Normal rats received 0.5 ml (2% solution) of acacia,
II = diabetic rats treated with insulin 0.5I.U/kg, III = diabetic rats treated with 400 mg/kg extracts, IV = diabetic rats treated with 250 mg/kg extract, V = diabetic rats
treated with 100 mg/kg extracts, VI = diabetic rats untreated
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glucose contents were determined using enzymatic spectro-
scopic methods [21].
Tissue histology
The pancreatic tissue harvested from each group was fixed
in 10% buffered formalin for 7 days before subjecting the
tissues to routine histological processing techniques as
described by Grizzle et al. [22] and staining with Haema-
toxylin and Eosin (H and E). Each section was examined
under light microscope at high power magnification (×100
and x400) for structural changes. Photomicrographs were
taken using an attached digital camera.
Statistical analysis
Data analysis was done using Graph Pad Prism 6. One
way analysis of variance (ANOVA) was used to compare
means. One–way ANOVA was done followed by Dun-
nett’s multiple comparisons test of treated groups with
control. The results were expressed as Mean ± SEM.
Level of significance was set at p < 0.05.
Results
Antidiabetic activity of the root extract of Uvaria chamae
Table 1 is a summary of the results of the effect of the ex-
tract on the fasting blood glucose. There was an astro-
nomical increase in the plasma blood glucose levels of the
streptozotocin induced diabetic rats untreated compared
with the control from day one to the last day of the ex-
periment. There was also a significant (p < 0.05) increase
in the plasma glucose levels of the diabetic rats treated
with the extract and reference drug insulin compared with
the control on day one. This showed that the rats were
truly diabetic. However, on the 5th and 8th day (the last
day of the experiment), there was a significant (p < 0.05)
reduction of the plasma glucose levels of the diabetic rats
treated with the extract compared with the control. While
the plasma blood glucose levels of the diabetic rats treated
with insulin was significantly (p < 0.05) increased com-
pared with the control on the 5th and 8th day. The rats
treated with 100, 250 and 400 mg/kg body weight of the
extract showed a glucose reduction of 85.88, 80.00 and
85.48% respectively on the 5th day. However, on the 8th
day of the treatment, rats treated with 100, 250 and
400 mg/kg body weight of the extract showed a maximum
glucose reduction of 85.16, 81.50 and 86.02% respectively.
While the rats treated with the reference drug insulin at
the dose of 0.5 IU/kg body weight showed a glucose re-
duction of 25.43 and 63.28% on the 5th and 8th day
respectively.
Effect of Uvaria chamae on plasma lipid profile
Table 2 is a summary of the results of the effects of Uvaria
chamae on plasma lipid profile in diabetic rats. The
plasma cholesterol and LDL levels of diabetic rats treated
with the extracts were significantly reduced (p < 0.05)
compared with the control. However, there was an in-
crease in the HDL levels. The increase was not significant
compared with the control. There was also a significant
reduction (p < 0.05) in the plasma cholesterol and LDL
levels of the diabetic rats treated with insulin. The plasma
triglyceride levels of the diabetic rats untreated was signifi-
cantly increased (p < 0.05) compared with the control.
Effect of Uvaria chamae on other biochemical parameters
Table 3 is the summary of the result of the effects of
Uvaria chamae on the other biochemical parameters.
There was a significant decrease (p < 0.05) in the plasma
protein levels of the diabetic rats treated with 400 mg/kg
Fig. 1 Photomicrograph of the pancreas of normal rat (positive control); H&E x100-A and x400-B showing Islet of Langerhans in plate a (Red arrow) and
intact islet cells in plate b (encircled)
Table 4 Effect of Uvaria chamae on the body weight (g)
Group Day1 Day5 Day8
I 130.7 ± 17.9 135.7 ± 20.5 159.0 ± 2.1
II 137.7 ± 5.8 127.3 ± 16.8 167.0 ± 3.5
III 133.7 ± 5.6 140.0 ± 6.1 122.7 ± 9.3*
IV 121.0 ± 4.4 107.7 ± 4.1 102.3 ± 1.5*
V 124.0 ± 7.2 118.3 ± 7.1 120.0 ± 2.9*
VI 135.0 ± 6.4 124.0 ± 2.7 118.3 ± 3.5*
*Significant difference (p < 0.05; n = 5) between the Mean ± SEM of test group
vs. control. Group I = (control) Normal rats received 0.5 ml (2% solution) of
acacia, II = diabetic rats treated with insulin 0.5I.U/kg, III = diabetic rats treated
with 400 mg/kg extract, IV = diabetic rats treated with 250 mg/kg extract,
V = diabetic rats treated with 100 mg/kg extracts, VI = diabetic rats untreated
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of the extract and the diabetic rats untreated compared
with the control. The plasma albumin levels of the dia-
betic rats treated with insulin and 400 mg/kg of the ex-
tract were significantly reduced (p < 0.05) compared with
the control. There was a significant increase (p < 0.05) in
the plasma creatinine levels of the diabetic rats un-
treated compared with the control. The plasma urea
levels of the diabetic rats treated with insulin, 400 mg/kg
and 250 mg/kg of the extracts were significantly in-
creased (p < 0.05) compared with the control. There was
also a significant increase (p < 0.05) in the plasma urea
level of the diabetic rats untreated compared with the
control. There was no significant change in the plasma
AST, ALT and ALP of the diabetic rats treated with the
extract compared with the control. However, there was a
significant increase (p < 0.05) in the plasma AST, ALT
and ALP of the diabetic rats treated with insulin com-
pared with the control. There was also a significant in-
crease in (p < 0.05) the plasma AST and ALT levels of
the diabetic rats untreated compared with the control.
Effect of Uvaria chamae on the body weight
The summary of the effects of the extract on the body
weight of the rats is shown (Table 4). There was weight
reduction in the rats treated with 100 and 250 mg/kg
body weight of the extracts on the 5th day. This weight
reduction was not statistically significant. However, on
the 8th day there was a significant reduction (p < 0.05) in
the weight of the rats treated with 100, 250 and 400 mg/
kg body weight of the extracts compared with the con-
trol. The diabetic rats untreated showed a reduction in
weight on the 5th day. The weight reduction was signifi-
cant (p < 0.05) on the 8th day.
Histopathological studies
The photomicrographs showing the histological features
of the pancreas are shown in Figs. 1, 2, 3, 4, 5 and 6.
The pancreas of the normal rats (Fig. 1) showed sheets
of normal sized glands lined by columnar epithelium
with basally located nuclei surrounded by vesicular cyto-
plasm. Interspersed within these glands are islands of
normal sized Islet of Langerhans. The pancreas of the
diabetic rats untreated (Fig. 2) showed sheets of small
sized glands lined by columnar epithelium with basally
located nucleus and vesicular cytoplasm. No Islet of
Langerhan was seen. The pancreas of the diabetic rats
(Figs. 3, 4, and 5), treated with the extract 100, 250 and
400 mg/kg body weight respectively, showed clusters of
variably sized regenerated Islet of Langerhans within
sheets of normal exocrine pancreas. However, the pan-
creas of the diabetic rats treated with insulin (Fig. 6),
showed sheets of exocrine glands with parenchymal dis-
tortion. No Islet of Langerhan seen.
Discussion
Diabetes mellitus is a disease that affects the quality of
life and life expectancy of its victim’s worldwide [23].
Many deaths of diabetic subjects have been attributed to
Fig. 3 Photomicrograph of the pancreas of diabetic rat treated with 100 mg/kg of Uvaria chamae extract (H&E x100-A and x400-B) showing
regenerated cells in the Islet of Langerhans (See plate a; Red arrow) and regenerated islet cells in plate b (encircled)
Fig. 2 Photomicrograph of the pancreas of diabetic rat untreated (negative control); H&E x100 a and x400 b with no Islet of Langerhans
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hyperglycemia and its accompanied vascular diseases.
Hyperglycemia in particular, is the primary clinical mani-
festation of diabetes [24] and is thought to contribute to
diabetic complications by altering vascular cellular me-
tabolism, vascular matrix and circulating lipoproteins
[25]. The major goal in the treatment of diabetes has
been to keep both short-term and long-term glucose
levels within acceptable limits, thereby reducing the risk
of long term complications [26].
The result of this study showed that there was a signifi-
cant reduction in the blood glucose levels of all the dia-
betic rats treated with the extract compared with the
control. The 100, 250 and 400 mg/kg body weight of the
Uvaria chamae extract achieved diabetic control at the 5th
day of treatment with a glucose reduction of 85.88, 80.00
and 85.48% respectively. This diabetic control was main-
tained till the end of the experiment. This marked reduc-
tion in plasma glucose concentration may be as a result of
increased release of insulin from regenerated beta cells of
the pancreas (Figs. 3, 4 and 5). The presence of phyto-
chemicals such as flavonoids, alkaloids and tannins in the
extract as reported in our previous study [9] may also have
contributed to its antidiabetic activity.
Besides hyperglycemia, diabetes mellitus is highly
characterized by elevated levels of triglycerides and
cholesterol in the blood associated with a modern life-
style and increased consumption of a high fat diet [27].
The reduced absorption of free fatty acids and free
cholesterol by inhibition of pancreatic lipase and pancre-
atic cholesterol esterase reduces hyperlipidemia associ-
ated with diabetes mellitus [28, 29]. This study revealed
that the extract lowered the plasma total cholesterol and
LDL-cholesterol levels significantly in the treated
diabetic rats. This clearly demonstrated the presence of
hypolipidemic agents in the extract. The hypolipidemic
activity of the extract may be due to the inhibition of
pancreatic lipase and pancreatic cholesterol esterase.
The reduced plasma LDL-cholesterol reduces the risk of
developing cardiovascular disease [30].
Persistent hyperglycemia causes increase in cellular
glucose level in tissues undergoing insulin-independent
glucose uptake such as eye lens, retina, kidney, and per-
ipheral nerves, leading to secondary late stage diabetic
complications. Influx of excess glucose into polyol path-
way causes accumulation of sorbitol in the tissues,
resulting in hyperosmotic stress to the cells. This is pos-
tulated to be the primary cause of diabetic complications
which include nephropathy, retinopathy, cataract, and
neuropathy [31]. Creatinine is the most commonly used
indicator of renal function. A raised plasma level of cre-
atinine is a recognised marker of renal dysfunction [32].
The significant increase in the plasma creatinine levels
of the diabetic rats’ untreated indicated renal impair-
ment in this group of rats. Therefore, persistent hyper-
glycemia due to poorly controlled diabetes mellitus may
lead to diabetic nephropathy. A number of extra renal
Fig. 5 Photomicrograph of the pancreas of diabetic rat treated with 400 mg/kg of Uvaria chamae extract (H&Ex100-A and x400-B) showing
regenerated cells in the Islet of Langerhans (See plate a; Red arrow) and regenerated islet cells in plate b (encircled)
Fig. 4 Photomicrograph of the pancreas of diabetic rat treated with 250 mg/kg of Uvaria chamae extract (H&E x100-A and x400-B) showing
regenerated cells in the Islet of Langerhans (See plate a; Red arrow) and regenerated islet cells in plate b (encircled)
Emordi et al. BMC Complementary and Alternative Medicine  (2016) 16:468 Page 6 of 8
factors influence the circulating urea concentration lim-
iting its value as a test of kidney function. For example
plasma urea concentration is increased by high protein
diet, increased protein catabolism and dehydration. In
the above pre-renal situations, the plasma creatinine
concentration is usually normal [33]. The raised plasma
urea seen in the diabetic rats treated with insulin and
the extract could be as a result of dehydration or in-
duced diabetic state from streptozotocin. This assertion
is corroborated by Parvizi et al. [34], who reported that
streptozotocin induced diabetes caused a significant in-
crease in serum blood urea nitrogen level in type1 dia-
betes mellitus. ALT, AST and ALP are part of the liver
enzymes [35]. They are frequently used to diagnose or
screen for hepatobiliary disease, examine the progression
of a disease as well as to monitor or detect the hepato-
toxicity that may arise from the use of drugs or sub-
stances [36, 37]. The heart also releases AST and ALT,
and an elevation in their plasma concentrations is an in-
dicator of liver and heart damage [19]. The results in
this study showed that the activities of AST and ALT in
the plasma of diabetic rats untreated were markedly ele-
vated. These enzymes are usually found in large quan-
tities in the liver where they play an important role in
the metabolism of amino acid [38]. However, as a result
of damage or toxicity to the liver, these enzymes may
leak from the hepatocytes into the circulation where
their levels become elevated [39]. Therefore, the elevated
plasma levels of AST and ALT in the diabetic untreated
rats suggested liver and heart damage. Administration of
the root extract of Uvaria chamae considerably reduced
the elevated levels of AST and ALT in the diabetic rats.
This showed that the extract is hepatocellular and
cardio-protective. However, the elevated levels of AST,
ALT and ALP in the diabetic rats treated with insulin
during the period of the experiment could be as a result
of damage to the liver and the heart from poorly con-
trolled diabetes mellitus. Elevations of transaminases
and alkaline phosphatase are common in diabetes melli-
tus [40]. Weight loss is considered an important aspect
of therapy for patients with diabetes. Excess weight
places greater direct demand on the beta-cell and also
aggravates insulin resistance. Numerous studies have
shown that weight loss in patients with diabetes can re-
sult in improvement in glucose levels [41]. The results of
this study revealed that there was a significant weight re-
duction in the diabetic rats treated with the extract com-
pared with the control. The weight loss may be due to
suppression of appetite.
Conclusion
This study showed that Uvaria chamae has antidiabetic
and hypolipidemic activities. From the study the extract
not only improved glycemic and lipidemic control but
also caused weight loss, making it beneficial for diabetic
patients that are overweight. These findings reduce the
risk of developing cardiovascular disease and give cre-
dence to the use of the extract traditionally in the treat-
ment of diabetes mellitus. The study also revealed that
the extract is hepatocellular and cardio-protective.
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